📢 FDA approves Nerandomilast in IPF, first new pulmonary fibrosis drug in over a decade. Slower progression of FVC decline and a (non-significant) trend toward improved mortality (FIBRONEER-IPF, FIBRONEER-ILD)
#pulmsky #ILD #IPF
druganddeviceworld.com/2025/10/02/e...
druganddeviceworld.com
ERS 2025: Boehringer shares additional data for lung fibrosis therapy
Pooled Phase III data show Boehringer Ingelheim's nerandomilast may reduce death risk in pulmonary fibrosis, IPF and PPF.
